3 results
Safety Run-in (SRI) part:To confirm the recommended phase 2 dose (RP2D) of NIS793 or any other investigational drug(s), in combination with SOC anti-cancer therapy. In protocol amendment 1, an arm with tislelizumab has been added. In this arm, the…
Augmented Reality cues to reduce Freezing of Gait during turning in persons with Parkinson*s disease
The primary objective of this study is to investigate the effect of visual turning-cues presented in augmented reality on the severity of freezing of gait evoked during turning in patients with Parkinson*s disease. This effect is compared to that of…
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC.This study aims to explore whether blockade of Transforming…